Thyrosafe

Hypothyroidism, Goiter, Folic Acid Deficiency + 9 more
Treatment
4 FDA approvals
20 Active Studies for Thyrosafe

What is Thyrosafe

Potassium IodideThe Generic name of this drug
Treatment SummaryPotassium Iodide (SSKI) is a medication used to treat severe hyperthyroidism, also known as thyroid storm or thyrotoxic crisis. It can also be used in cases of radioiodine contamination or to prepare thyrotoxic patients for thyroidectomy.
Sskiis the brand name
Thyrosafe Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Sski
Potassium Iodide
1973
7

Approved as Treatment by the FDA

Potassium Iodide, also called Sski, is approved by the FDA for 4 uses including Acute radiation sickness and Acute Radiation Syndrome .
Acute radiation sickness
Acute Radiation Syndrome
prophylaxis of radiation poisoning
nuclear radiation emergency

Effectiveness

How Thyrosafe Affects PatientsKI works by preventing the thyroid gland from producing and releasing hormones. This reduces the amount of blood that goes to the thyroid gland, makes the tissue firmer, and makes the cells smaller. It also helps to increase iodine levels. Taking KI can help protect against radiation exposure by blocking radioactive iodine isotopes from going to the thyroid gland, which lowers the risk of getting cancer in the thyroid.

When to interrupt dosage

The recommended dose of Thyrosafe is contingent upon the diagnosed condition, such as Thyroid Cancer, Disinfection and Acute radiation sickness. The portion of dosage may differ as per the technique of delivery (e.g. Tablet or Kit) noted in the table beneath.
Condition
Dosage
Administration
Nutritional supplementation
, 1000.0 mg/mL, 65.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 20.0 mg/mL, 65.0 mg, 0.075 mg, 0.15 mg, 2.5 %, 130.0 mg, 3.3 %, 160.0 mg, 325.0 mg, 0.1 mg, 0.3 mg, 32.5 mg, 24.0 mg/mL, 150.0 mg, 0.175 mg, 0.25 mg, 0.2 mg, 0.09 mg, 0.0083 mg, 0.05 mg, 0.016 mg, 0.01 mg, 0.5 mg, 0.025 mg, 0.08 mg, 0.0375 mg, 5.0 mg, 0.028 mg, 0.22 mg, 0.03 mg, 0.0304 mg, 0.04 mg, 0.001 mg/mL, 0.0000088 mg/mg, 0.056 mg, 180.0 mg, 0.013 mg/mL, 1400.0 mg/mL, 0.00000525 mg/mg, 0.00000375 mg/mg, 0.00000133 mg/mg, 0.01 mg/mL, 0.0000074 mg/mg, 0.00005 mg/mg, 0.000016 mg/mg, 0.005 mg/mL, 75.0 mg/mL, 16.0 mg/mL, 25.0 mg/mL, 33.0 mg/mL, 16.7 mg/mL, 0.01105 mg/mg, 18.0 mg/mL, 0.075 mg/mL, 0.29 mg
Oral, Solution, Solution - Oral, , Topical, Liquid - Oral, Liquid, Liquid - Topical, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Syrup, Syrup - Oral, Tincture - Topical, Intravenous, Liquid - Intravenous, Tincture, Solution - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, gelatin coated - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Powder - Oral, Powder, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Powder - Topical, Pill - Oral, Pill, Tablet, effervescent - Oral, Tablet, effervescent, Injection, solution, Tablet, chewable, Tablet, chewable - Oral, Injection, solution - Intravenous, Bar, chewable, Bar, chewable - Oral, Solution - Intravenous, Solution / drops, Solution / drops - Oral
nuclear radiation emergency
, 1000.0 mg/mL, 65.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 20.0 mg/mL, 65.0 mg, 0.075 mg, 0.15 mg, 2.5 %, 130.0 mg, 3.3 %, 160.0 mg, 325.0 mg, 0.1 mg, 0.3 mg, 32.5 mg, 24.0 mg/mL, 150.0 mg, 0.175 mg, 0.25 mg, 0.2 mg, 0.09 mg, 0.0083 mg, 0.05 mg, 0.016 mg, 0.01 mg, 0.5 mg, 0.025 mg, 0.08 mg, 0.0375 mg, 5.0 mg, 0.028 mg, 0.22 mg, 0.03 mg, 0.0304 mg, 0.04 mg, 0.001 mg/mL, 0.0000088 mg/mg, 0.056 mg, 180.0 mg, 0.013 mg/mL, 1400.0 mg/mL, 0.00000525 mg/mg, 0.00000375 mg/mg, 0.00000133 mg/mg, 0.01 mg/mL, 0.0000074 mg/mg, 0.00005 mg/mg, 0.000016 mg/mg, 0.005 mg/mL, 75.0 mg/mL, 16.0 mg/mL, 25.0 mg/mL, 33.0 mg/mL, 16.7 mg/mL, 0.01105 mg/mg, 18.0 mg/mL, 0.075 mg/mL, 0.29 mg
Oral, Solution, Solution - Oral, , Topical, Liquid - Oral, Liquid, Liquid - Topical, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Syrup, Syrup - Oral, Tincture - Topical, Intravenous, Liquid - Intravenous, Tincture, Solution - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, gelatin coated - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Powder - Oral, Powder, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Powder - Topical, Pill - Oral, Pill, Tablet, effervescent - Oral, Tablet, effervescent, Injection, solution, Tablet, chewable, Tablet, chewable - Oral, Injection, solution - Intravenous, Bar, chewable, Bar, chewable - Oral, Solution - Intravenous, Solution / drops, Solution / drops - Oral
Thyroid Cancer
, 1000.0 mg/mL, 65.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 20.0 mg/mL, 65.0 mg, 0.075 mg, 0.15 mg, 2.5 %, 130.0 mg, 3.3 %, 160.0 mg, 325.0 mg, 0.1 mg, 0.3 mg, 32.5 mg, 24.0 mg/mL, 150.0 mg, 0.175 mg, 0.25 mg, 0.2 mg, 0.09 mg, 0.0083 mg, 0.05 mg, 0.016 mg, 0.01 mg, 0.5 mg, 0.025 mg, 0.08 mg, 0.0375 mg, 5.0 mg, 0.028 mg, 0.22 mg, 0.03 mg, 0.0304 mg, 0.04 mg, 0.001 mg/mL, 0.0000088 mg/mg, 0.056 mg, 180.0 mg, 0.013 mg/mL, 1400.0 mg/mL, 0.00000525 mg/mg, 0.00000375 mg/mg, 0.00000133 mg/mg, 0.01 mg/mL, 0.0000074 mg/mg, 0.00005 mg/mg, 0.000016 mg/mg, 0.005 mg/mL, 75.0 mg/mL, 16.0 mg/mL, 25.0 mg/mL, 33.0 mg/mL, 16.7 mg/mL, 0.01105 mg/mg, 18.0 mg/mL, 0.075 mg/mL, 0.29 mg
Oral, Solution, Solution - Oral, , Topical, Liquid - Oral, Liquid, Liquid - Topical, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Syrup, Syrup - Oral, Tincture - Topical, Intravenous, Liquid - Intravenous, Tincture, Solution - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, gelatin coated - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Powder - Oral, Powder, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Powder - Topical, Pill - Oral, Pill, Tablet, effervescent - Oral, Tablet, effervescent, Injection, solution, Tablet, chewable, Tablet, chewable - Oral, Injection, solution - Intravenous, Bar, chewable, Bar, chewable - Oral, Solution - Intravenous, Solution / drops, Solution / drops - Oral
Disinfection
, 1000.0 mg/mL, 65.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 20.0 mg/mL, 65.0 mg, 0.075 mg, 0.15 mg, 2.5 %, 130.0 mg, 3.3 %, 160.0 mg, 325.0 mg, 0.1 mg, 0.3 mg, 32.5 mg, 24.0 mg/mL, 150.0 mg, 0.175 mg, 0.25 mg, 0.2 mg, 0.09 mg, 0.0083 mg, 0.05 mg, 0.016 mg, 0.01 mg, 0.5 mg, 0.025 mg, 0.08 mg, 0.0375 mg, 5.0 mg, 0.028 mg, 0.22 mg, 0.03 mg, 0.0304 mg, 0.04 mg, 0.001 mg/mL, 0.0000088 mg/mg, 0.056 mg, 180.0 mg, 0.013 mg/mL, 1400.0 mg/mL, 0.00000525 mg/mg, 0.00000375 mg/mg, 0.00000133 mg/mg, 0.01 mg/mL, 0.0000074 mg/mg, 0.00005 mg/mg, 0.000016 mg/mg, 0.005 mg/mL, 75.0 mg/mL, 16.0 mg/mL, 25.0 mg/mL, 33.0 mg/mL, 16.7 mg/mL, 0.01105 mg/mg, 18.0 mg/mL, 0.075 mg/mL, 0.29 mg
Oral, Solution, Solution - Oral, , Topical, Liquid - Oral, Liquid, Liquid - Topical, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Syrup, Syrup - Oral, Tincture - Topical, Intravenous, Liquid - Intravenous, Tincture, Solution - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, gelatin coated - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Powder - Oral, Powder, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Powder - Topical, Pill - Oral, Pill, Tablet, effervescent - Oral, Tablet, effervescent, Injection, solution, Tablet, chewable, Tablet, chewable - Oral, Injection, solution - Intravenous, Bar, chewable, Bar, chewable - Oral, Solution - Intravenous, Solution / drops, Solution / drops - Oral
Iron deficiency
, 1000.0 mg/mL, 65.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 20.0 mg/mL, 65.0 mg, 0.075 mg, 0.15 mg, 2.5 %, 130.0 mg, 3.3 %, 160.0 mg, 325.0 mg, 0.1 mg, 0.3 mg, 32.5 mg, 24.0 mg/mL, 150.0 mg, 0.175 mg, 0.25 mg, 0.2 mg, 0.09 mg, 0.0083 mg, 0.05 mg, 0.016 mg, 0.01 mg, 0.5 mg, 0.025 mg, 0.08 mg, 0.0375 mg, 5.0 mg, 0.028 mg, 0.22 mg, 0.03 mg, 0.0304 mg, 0.04 mg, 0.001 mg/mL, 0.0000088 mg/mg, 0.056 mg, 180.0 mg, 0.013 mg/mL, 1400.0 mg/mL, 0.00000525 mg/mg, 0.00000375 mg/mg, 0.00000133 mg/mg, 0.01 mg/mL, 0.0000074 mg/mg, 0.00005 mg/mg, 0.000016 mg/mg, 0.005 mg/mL, 75.0 mg/mL, 16.0 mg/mL, 25.0 mg/mL, 33.0 mg/mL, 16.7 mg/mL, 0.01105 mg/mg, 18.0 mg/mL, 0.075 mg/mL, 0.29 mg
Oral, Solution, Solution - Oral, , Topical, Liquid - Oral, Liquid, Liquid - Topical, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Syrup, Syrup - Oral, Tincture - Topical, Intravenous, Liquid - Intravenous, Tincture, Solution - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, gelatin coated - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Powder - Oral, Powder, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Powder - Topical, Pill - Oral, Pill, Tablet, effervescent - Oral, Tablet, effervescent, Injection, solution, Tablet, chewable, Tablet, chewable - Oral, Injection, solution - Intravenous, Bar, chewable, Bar, chewable - Oral, Solution - Intravenous, Solution / drops, Solution / drops - Oral
Hypothyroidism
, 1000.0 mg/mL, 65.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 20.0 mg/mL, 65.0 mg, 0.075 mg, 0.15 mg, 2.5 %, 130.0 mg, 3.3 %, 160.0 mg, 325.0 mg, 0.1 mg, 0.3 mg, 32.5 mg, 24.0 mg/mL, 150.0 mg, 0.175 mg, 0.25 mg, 0.2 mg, 0.09 mg, 0.0083 mg, 0.05 mg, 0.016 mg, 0.01 mg, 0.5 mg, 0.025 mg, 0.08 mg, 0.0375 mg, 5.0 mg, 0.028 mg, 0.22 mg, 0.03 mg, 0.0304 mg, 0.04 mg, 0.001 mg/mL, 0.0000088 mg/mg, 0.056 mg, 180.0 mg, 0.013 mg/mL, 1400.0 mg/mL, 0.00000525 mg/mg, 0.00000375 mg/mg, 0.00000133 mg/mg, 0.01 mg/mL, 0.0000074 mg/mg, 0.00005 mg/mg, 0.000016 mg/mg, 0.005 mg/mL, 75.0 mg/mL, 16.0 mg/mL, 25.0 mg/mL, 33.0 mg/mL, 16.7 mg/mL, 0.01105 mg/mg, 18.0 mg/mL, 0.075 mg/mL, 0.29 mg
Oral, Solution, Solution - Oral, , Topical, Liquid - Oral, Liquid, Liquid - Topical, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Syrup, Syrup - Oral, Tincture - Topical, Intravenous, Liquid - Intravenous, Tincture, Solution - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, gelatin coated - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Powder - Oral, Powder, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Powder - Topical, Pill - Oral, Pill, Tablet, effervescent - Oral, Tablet, effervescent, Injection, solution, Tablet, chewable, Tablet, chewable - Oral, Injection, solution - Intravenous, Bar, chewable, Bar, chewable - Oral, Solution - Intravenous, Solution / drops, Solution / drops - Oral
Goiter
, 1000.0 mg/mL, 65.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 20.0 mg/mL, 65.0 mg, 0.075 mg, 0.15 mg, 2.5 %, 130.0 mg, 3.3 %, 160.0 mg, 325.0 mg, 0.1 mg, 0.3 mg, 32.5 mg, 24.0 mg/mL, 150.0 mg, 0.175 mg, 0.25 mg, 0.2 mg, 0.09 mg, 0.0083 mg, 0.05 mg, 0.016 mg, 0.01 mg, 0.5 mg, 0.025 mg, 0.08 mg, 0.0375 mg, 5.0 mg, 0.028 mg, 0.22 mg, 0.03 mg, 0.0304 mg, 0.04 mg, 0.001 mg/mL, 0.0000088 mg/mg, 0.056 mg, 180.0 mg, 0.013 mg/mL, 1400.0 mg/mL, 0.00000525 mg/mg, 0.00000375 mg/mg, 0.00000133 mg/mg, 0.01 mg/mL, 0.0000074 mg/mg, 0.00005 mg/mg, 0.000016 mg/mg, 0.005 mg/mL, 75.0 mg/mL, 16.0 mg/mL, 25.0 mg/mL, 33.0 mg/mL, 16.7 mg/mL, 0.01105 mg/mg, 18.0 mg/mL, 0.075 mg/mL, 0.29 mg
Oral, Solution, Solution - Oral, , Topical, Liquid - Oral, Liquid, Liquid - Topical, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Syrup, Syrup - Oral, Tincture - Topical, Intravenous, Liquid - Intravenous, Tincture, Solution - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, gelatin coated - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Powder - Oral, Powder, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Powder - Topical, Pill - Oral, Pill, Tablet, effervescent - Oral, Tablet, effervescent, Injection, solution, Tablet, chewable, Tablet, chewable - Oral, Injection, solution - Intravenous, Bar, chewable, Bar, chewable - Oral, Solution - Intravenous, Solution / drops, Solution / drops - Oral
Folic Acid Deficiency
, 1000.0 mg/mL, 65.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 20.0 mg/mL, 65.0 mg, 0.075 mg, 0.15 mg, 2.5 %, 130.0 mg, 3.3 %, 160.0 mg, 325.0 mg, 0.1 mg, 0.3 mg, 32.5 mg, 24.0 mg/mL, 150.0 mg, 0.175 mg, 0.25 mg, 0.2 mg, 0.09 mg, 0.0083 mg, 0.05 mg, 0.016 mg, 0.01 mg, 0.5 mg, 0.025 mg, 0.08 mg, 0.0375 mg, 5.0 mg, 0.028 mg, 0.22 mg, 0.03 mg, 0.0304 mg, 0.04 mg, 0.001 mg/mL, 0.0000088 mg/mg, 0.056 mg, 180.0 mg, 0.013 mg/mL, 1400.0 mg/mL, 0.00000525 mg/mg, 0.00000375 mg/mg, 0.00000133 mg/mg, 0.01 mg/mL, 0.0000074 mg/mg, 0.00005 mg/mg, 0.000016 mg/mg, 0.005 mg/mL, 75.0 mg/mL, 16.0 mg/mL, 25.0 mg/mL, 33.0 mg/mL, 16.7 mg/mL, 0.01105 mg/mg, 18.0 mg/mL, 0.075 mg/mL, 0.29 mg
Oral, Solution, Solution - Oral, , Topical, Liquid - Oral, Liquid, Liquid - Topical, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Syrup, Syrup - Oral, Tincture - Topical, Intravenous, Liquid - Intravenous, Tincture, Solution - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, gelatin coated - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Powder - Oral, Powder, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Powder - Topical, Pill - Oral, Pill, Tablet, effervescent - Oral, Tablet, effervescent, Injection, solution, Tablet, chewable, Tablet, chewable - Oral, Injection, solution - Intravenous, Bar, chewable, Bar, chewable - Oral, Solution - Intravenous, Solution / drops, Solution / drops - Oral
prophylaxis of radiation poisoning
, 1000.0 mg/mL, 65.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 20.0 mg/mL, 65.0 mg, 0.075 mg, 0.15 mg, 2.5 %, 130.0 mg, 3.3 %, 160.0 mg, 325.0 mg, 0.1 mg, 0.3 mg, 32.5 mg, 24.0 mg/mL, 150.0 mg, 0.175 mg, 0.25 mg, 0.2 mg, 0.09 mg, 0.0083 mg, 0.05 mg, 0.016 mg, 0.01 mg, 0.5 mg, 0.025 mg, 0.08 mg, 0.0375 mg, 5.0 mg, 0.028 mg, 0.22 mg, 0.03 mg, 0.0304 mg, 0.04 mg, 0.001 mg/mL, 0.0000088 mg/mg, 0.056 mg, 180.0 mg, 0.013 mg/mL, 1400.0 mg/mL, 0.00000525 mg/mg, 0.00000375 mg/mg, 0.00000133 mg/mg, 0.01 mg/mL, 0.0000074 mg/mg, 0.00005 mg/mg, 0.000016 mg/mg, 0.005 mg/mL, 75.0 mg/mL, 16.0 mg/mL, 25.0 mg/mL, 33.0 mg/mL, 16.7 mg/mL, 0.01105 mg/mg, 18.0 mg/mL, 0.075 mg/mL, 0.29 mg
Oral, Solution, Solution - Oral, , Topical, Liquid - Oral, Liquid, Liquid - Topical, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Syrup, Syrup - Oral, Tincture - Topical, Intravenous, Liquid - Intravenous, Tincture, Solution - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, gelatin coated - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Powder - Oral, Powder, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Powder - Topical, Pill - Oral, Pill, Tablet, effervescent - Oral, Tablet, effervescent, Injection, solution, Tablet, chewable, Tablet, chewable - Oral, Injection, solution - Intravenous, Bar, chewable, Bar, chewable - Oral, Solution - Intravenous, Solution / drops, Solution / drops - Oral
Acute Radiation Syndrome
, 1000.0 mg/mL, 65.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 20.0 mg/mL, 65.0 mg, 0.075 mg, 0.15 mg, 2.5 %, 130.0 mg, 3.3 %, 160.0 mg, 325.0 mg, 0.1 mg, 0.3 mg, 32.5 mg, 24.0 mg/mL, 150.0 mg, 0.175 mg, 0.25 mg, 0.2 mg, 0.09 mg, 0.0083 mg, 0.05 mg, 0.016 mg, 0.01 mg, 0.5 mg, 0.025 mg, 0.08 mg, 0.0375 mg, 5.0 mg, 0.028 mg, 0.22 mg, 0.03 mg, 0.0304 mg, 0.04 mg, 0.001 mg/mL, 0.0000088 mg/mg, 0.056 mg, 180.0 mg, 0.013 mg/mL, 1400.0 mg/mL, 0.00000525 mg/mg, 0.00000375 mg/mg, 0.00000133 mg/mg, 0.01 mg/mL, 0.0000074 mg/mg, 0.00005 mg/mg, 0.000016 mg/mg, 0.005 mg/mL, 75.0 mg/mL, 16.0 mg/mL, 25.0 mg/mL, 33.0 mg/mL, 16.7 mg/mL, 0.01105 mg/mg, 18.0 mg/mL, 0.075 mg/mL, 0.29 mg
Oral, Solution, Solution - Oral, , Topical, Liquid - Oral, Liquid, Liquid - Topical, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Syrup, Syrup - Oral, Tincture - Topical, Intravenous, Liquid - Intravenous, Tincture, Solution - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, gelatin coated - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Powder - Oral, Powder, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Powder - Topical, Pill - Oral, Pill, Tablet, effervescent - Oral, Tablet, effervescent, Injection, solution, Tablet, chewable, Tablet, chewable - Oral, Injection, solution - Intravenous, Bar, chewable, Bar, chewable - Oral, Solution - Intravenous, Solution / drops, Solution / drops - Oral
Iodine Deficiency
, 1000.0 mg/mL, 65.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 20.0 mg/mL, 65.0 mg, 0.075 mg, 0.15 mg, 2.5 %, 130.0 mg, 3.3 %, 160.0 mg, 325.0 mg, 0.1 mg, 0.3 mg, 32.5 mg, 24.0 mg/mL, 150.0 mg, 0.175 mg, 0.25 mg, 0.2 mg, 0.09 mg, 0.0083 mg, 0.05 mg, 0.016 mg, 0.01 mg, 0.5 mg, 0.025 mg, 0.08 mg, 0.0375 mg, 5.0 mg, 0.028 mg, 0.22 mg, 0.03 mg, 0.0304 mg, 0.04 mg, 0.001 mg/mL, 0.0000088 mg/mg, 0.056 mg, 180.0 mg, 0.013 mg/mL, 1400.0 mg/mL, 0.00000525 mg/mg, 0.00000375 mg/mg, 0.00000133 mg/mg, 0.01 mg/mL, 0.0000074 mg/mg, 0.00005 mg/mg, 0.000016 mg/mg, 0.005 mg/mL, 75.0 mg/mL, 16.0 mg/mL, 25.0 mg/mL, 33.0 mg/mL, 16.7 mg/mL, 0.01105 mg/mg, 18.0 mg/mL, 0.075 mg/mL, 0.29 mg
Oral, Solution, Solution - Oral, , Topical, Liquid - Oral, Liquid, Liquid - Topical, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Syrup, Syrup - Oral, Tincture - Topical, Intravenous, Liquid - Intravenous, Tincture, Solution - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, gelatin coated - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Powder - Oral, Powder, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Powder - Topical, Pill - Oral, Pill, Tablet, effervescent - Oral, Tablet, effervescent, Injection, solution, Tablet, chewable, Tablet, chewable - Oral, Injection, solution - Intravenous, Bar, chewable, Bar, chewable - Oral, Solution - Intravenous, Solution / drops, Solution / drops - Oral
Disinfection
, 1000.0 mg/mL, 65.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 20.0 mg/mL, 65.0 mg, 0.075 mg, 0.15 mg, 2.5 %, 130.0 mg, 3.3 %, 160.0 mg, 325.0 mg, 0.1 mg, 0.3 mg, 32.5 mg, 24.0 mg/mL, 150.0 mg, 0.175 mg, 0.25 mg, 0.2 mg, 0.09 mg, 0.0083 mg, 0.05 mg, 0.016 mg, 0.01 mg, 0.5 mg, 0.025 mg, 0.08 mg, 0.0375 mg, 5.0 mg, 0.028 mg, 0.22 mg, 0.03 mg, 0.0304 mg, 0.04 mg, 0.001 mg/mL, 0.0000088 mg/mg, 0.056 mg, 180.0 mg, 0.013 mg/mL, 1400.0 mg/mL, 0.00000525 mg/mg, 0.00000375 mg/mg, 0.00000133 mg/mg, 0.01 mg/mL, 0.0000074 mg/mg, 0.00005 mg/mg, 0.000016 mg/mg, 0.005 mg/mL, 75.0 mg/mL, 16.0 mg/mL, 25.0 mg/mL, 33.0 mg/mL, 16.7 mg/mL, 0.01105 mg/mg, 18.0 mg/mL, 0.075 mg/mL, 0.29 mg
Oral, Solution, Solution - Oral, , Topical, Liquid - Oral, Liquid, Liquid - Topical, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Syrup, Syrup - Oral, Tincture - Topical, Intravenous, Liquid - Intravenous, Tincture, Solution - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, gelatin coated - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Powder - Oral, Powder, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Powder - Topical, Pill - Oral, Pill, Tablet, effervescent - Oral, Tablet, effervescent, Injection, solution, Tablet, chewable, Tablet, chewable - Oral, Injection, solution - Intravenous, Bar, chewable, Bar, chewable - Oral, Solution - Intravenous, Solution / drops, Solution / drops - Oral

Warnings

There are 20 known major drug interactions with Thyrosafe.
Common Thyrosafe Drug Interactions
Drug Name
Risk Level
Description
Amiloride
Major
The risk or severity of hyperkalemia can be increased when Potassium Iodide is combined with Amiloride.
Canrenoic acid
Major
The risk or severity of hyperkalemia can be increased when Potassium Iodide is combined with Canrenoic acid.
Canrenone
Major
The risk or severity of hyperkalemia can be increased when Potassium Iodide is combined with Canrenone.
Eplerenone
Major
The risk or severity of hyperkalemia can be increased when Potassium Iodide is combined with Eplerenone.
Iodide I-131
Major
The therapeutic efficacy of Iodide I-131 can be decreased when used in combination with Potassium Iodide.

Thyrosafe Novel Uses: Which Conditions Have a Clinical Trial Featuring Thyrosafe?

92 active clinical trials are presently underway to assess the effectiveness of Thyrosafe in providing prophylaxis against radiation poisoning, during Pregnancy and for Iodine Deficiency.
Condition
Clinical Trials
Trial Phases
Thyroid Cancer
38 Actively Recruiting
Phase 2, Not Applicable, Early Phase 1, Phase 1, Phase 3
Nutritional supplementation
0 Actively Recruiting
Hypothyroidism
6 Actively Recruiting
Phase 2, Phase 4, Phase 3, Not Applicable
Folic Acid Deficiency
0 Actively Recruiting
Disinfection
0 Actively Recruiting
Iron deficiency
6 Actively Recruiting
Phase 2, Not Applicable, Phase 4, Early Phase 1, Phase 3
nuclear radiation emergency
3 Actively Recruiting
Phase 1, Phase 2, Not Applicable
Disinfection
0 Actively Recruiting
Acute Radiation Syndrome
0 Actively Recruiting
prophylaxis of radiation poisoning
0 Actively Recruiting
Goiter
0 Actively Recruiting
Iodine Deficiency
0 Actively Recruiting

Patient Q&A Section about thyrosafe

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is ThyroSafe FDA approved?

"The FDA has approved ThyroSafe, a 65 mg KI Tablet, to help prevent radioactive iodine from getting into the thyroid gland during a nuclear radiation emergency."

Answered by AI

What company makes ThyroSafe?

"ThyroSafe is a potassium iodide tablet produced by Recipharm AB in Sweden. The company has over 20 years experience in manufacturing these types of tablets. They are meant to protect the thyroid against radioactive iodine that might be released during a nuclear emergency."

Answered by AI

What is ThyroSafe used for?

"This medicine is used to thin mucus and loosen congestion in the chest and throat. It is used in people with breathing problems that can be complicated by thick mucus, such as asthma, chronic bronchitis, or emphysema."

Answered by AI

How long is ThyroSafe good for?

"The NRC offers ThyroSafe™ 65 mg tablets that have a 10-year shelf life."

Answered by AI

Clinical Trials for Thyrosafe

Image of Columbia University Irving Medical Center in New York, United States.

Intravenous Iron for Iron Deficiency in Scoliosis

10 - 19
All Sexes
New York, NY
Adolescents and young adults undergoing spinal fusion surgery for the correction of scoliosis and other spinal deformity are at high risk of perioperative iron deficiency and anemia, yet the means and evidence for optimizing iron status have not been described in this setting. The proposed study is a randomized controlled trial of preoperative intravenous iron supplementation, to identify whether iron deficiency is a modifiable risk factor for adverse surgical outcomes such as red blood cell transfusion and diminished postoperative cognitive and physical capacity in this vulnerable population. Building evidence for patient blood management interventions such as iron supplementation is vital to ensuring high quality care of surgical patients and may reduce unnecessary transfusions amid recent blood shortages.
Phase 2 & 3
Waitlist Available
Columbia University Irving Medical Center
Have you considered Thyrosafe clinical trials? We made a collection of clinical trials featuring Thyrosafe, we think they might fit your search criteria.Go to Trials
Image of Cleveland Clinic in Cleveland, United States.

Gluten Free Diet for Hashimoto's Disease

Any Age
All Sexes
Cleveland, OH
Hashimoto's thyroiditis is an autoimmune condition that reduces functioning of the thyroid gland and can lead to a substantial decline in quality of life for patients, with impacted patients often describing unremitting brain fog, fatigue/malaise and weight gain leading to difficulty functioning in their jobs and homes. It is the most common cause of hypothyroidism in the U.S. and affects up to 10% of the global population. The typical treatment for Hashimoto's is thyroid hormone replacement with medications such as levothyroxine. However, despite adequate treatment as defined by thyroid hormone levels within the reference range, up to 10% of patients will experience persisting symptoms which can dramatically impair quality of life. While various theories have been postulated for the residual symptoms, several studies indicate that they are related to the thyroid autoimmunity, specifically the autoantibodies that are made by the immune system in Hashimoto's thyroiditis in response to the thyroid (ie thyroid peroxidase \[TPO\], thyroglobulin \[Tg\] antibody \[AB\]) and the associated inflammation with the immune response. Removal of thyroid (ie total thyroidectomy) reduces levels of these thyroid antibodies and results in significant improvement in quality-of-life. However, thyroidectomy is an invasive procedure with potential for morbidity such as damage to the recurrent laryngeal (nerve that controls the vocal cords and thus speech), bleeding and infection, so there is interest in other more conservative modalities for lowering the inflammation and autoimmune burden in Hashimoto's thyroiditis. In an effort to identify a less invasive approach for reducing the levels of thyroid antibodies and inflammation, attention has moved to the intersection of Hashimoto's thyroiditis and the gut. Hashimoto's has a strong association with autoimmune disorders impacting the gastrointestinal tract, in particular celiac disease and non-celiac gluten sensitivity (NCGS). NCGS is a condition where there are intestinal and extra-intestinal symptoms associated the consumption of gluten but no presence of anti-tissue transglutaminase antibodies (anti-tTG) which define Celiac Disease. This connection between Hashimoto's thyroiditis and sensitivity to gluten appears to be not only genetic, as those with Celiac Disease/NCGS and Hashimoto's thyroiditis have common HLA haplotypes, but also at the level of the intestine with gut microbiome dysfunction.
Recruiting
Has No Placebo
Cleveland Clinic
Image of The Medical Center in Bowling Green, United States.

Iron Supplementation for Heart Failure

18 - 100
All Sexes
Bowling Green, KY
The goal of this clinical trial is to learn which iron treatment works better for adults with congestive heart failure and low iron levels: intravenous (IV) iron given through a vein or oral (PO) iron taken by mouth. Participants must have heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF) and a transferrin-saturation (TSAT) level below 20 percent. The main questions the study will answer are: 1. Does IV iron raise walking distance on a 6-minute walk test more than oral iron after 24 weeks? 2. Does IV iron improve symptoms and quality of life more than oral iron? 3. How do the two treatments compare for safety, side effects, and hospital readmissions/ mortality? Researchers will compare IV ferric carboxymaltose with oral ferrous sulfate to see which option helps people feel and function better. What participants will do * Be randomly assigned by (like flipping a coin) to IV iron or oral iron. * Receive either a one-time IV iron infusion (with possible repeat at 12 weeks) or take iron pills twice each day for 24 weeks. * Visit the infusion clinic at 6 weeks for second dose of IV iron if needed. * Visit the clinic at 12 weeks for a follow-up to gather follow-up data including 1. A 6-minute walk test 2. Brief symptom and quality-of-life surveys 3. Blood tests to measure serum iron, ferritin, and transferrin saturation This study will help doctors decide whether IV or oral iron is the safer, more effective way to treat iron deficiency in people with heart failure in our local community.
Phase 4
Recruiting
The Medical CenterAmerican Regent, Inc.
Image of National Institutes of Health Clinical Center in Bethesda, United States.

177Lu-DOTA-EB-TATE for Thyroid Cancer

18 - 100
All Sexes
Bethesda, MD
Background: Oncocytic (Hurthle cell) thyroid cancer (HTC) is a rare disease with few treatment options. Researchers are developing a radioactive drug that targets a protein that appears in high numbers on HTC cancer cells. Objective: To test a radioactive drug (177LuDOTA-EB-TATE) in people with HTC. Eligibility: People aged 18 years and older with HTC. The HTC must have failed to respond to conventional radioactive treatment; it must also have spread to other parts of the body. Design: Participants will be screened. They will have a physical exam with blood tests. They will have imaging scans and a test of their heart function. 177LuDOTA-EB-TATE is infused into a vein. Participants will receive 4 infusions spaced 8 to 12 weeks apart. They will stay in the hospital for 4 to 10 days after each infusion. During and after each infusion, participants will remain in a lead-lined room until their radiation levels go down; this usually takes about 24 hours. Participants will have 4 to 6 follow-up visits in the weeks after each infusion. Procedures will vary at each visit, but may include more imaging scans; blood and urine tests; and tests of heart function. Participants will have 2 single-photon emission computerized tomography (SPECT) scans. SPECT scans show where the study drug is sticking to tumors or maybe other parts of their body. They will lie on a table while a machine rotates around them. Participants will fill in questionnaires about how their thyroid condition affects their life. Participants will have follow-ups visits for 5 years after their last study treatment.
Phase 1 & 2
Waitlist Available
National Institutes of Health Clinical CenterJoanna Klubo-Gwiezdzinska, M.D.
Image of Lombardi Comprehensive Cancer Center in Washington, United States.

Decision Aid for Thyroid Cancer

18+
All Sexes
Washington, United States
The goal of this study is to learn if a decision aid (DA) website helps people with thyroid cancer make informed decisions about radioactive iodine (RAI) treatment. The main questions it aims to answer are: - Does the decision aid help participants understand the risks and benefits of RAI treatment? - Does it help participants make choices that reflect what matters most to them? - How does the decision aid compare to usual care in supporting patients through this decision? Participants who have been recently diagnosed with intermediate-risk differentiated thyroid cancer (DTC) will be randomly assigned to one of two groups. One group will receive a special decision aid website. This site includes detailed information about RAI, short videos, drop-down menus with extra details, exercises to help clarify values, and tools to help patients prepare questions for their doctor. The other group will receive the American Cancer Society (ACS) website. This site gives basic information about RAI but does not include interactive tools and is not specific to intermediate-risk thyroid cancer. Follow up surveys will be sent to the participants periodically, first at the start of the study, and again at 1 week, 4 weeks, and 6 months later. Researchers will compare how the two groups differ in making informed decisions. The decision aid is meant to support, not replace, a conversation with the medical team. Doctor recommendations remain an important part of treatment decisions.
Waitlist Available
Has No Placebo
Lombardi Comprehensive Cancer Center (+4 Sites)
Have you considered Thyrosafe clinical trials? We made a collection of clinical trials featuring Thyrosafe, we think they might fit your search criteria.Go to Trials
Image of University of Calgary in Calgary, Canada.

Iron Supplements for Iron Deficiency

16 - 35
Female
Calgary, Canada
The goal of this clinical trial is to learn if different types and doses of oral iron supplements can improve iron levels, athletic performance, and gut health in young female athletes with low iron stores. The main questions it aims to answer are: * Does a low dose of yeast-bound iron improve iron status better than traditional iron supplements? * Do the different iron supplements cause fewer or more gastrointestinal (stomach) symptoms? * How do iron supplements affect exercise performance and gut bacteria? Researchers will compare three types of iron supplements: * A low-dose iron supplement (40 mg) * A low-dose yeast-bound iron supplement (40 mg) * A high-dose iron supplement (150 mg) This will help researchers find out which type of supplement is most effective and easiest on the stomach. Participants will: * Take one of the three assigned iron supplements every other day for 12 weeks * Complete fitness tests before and after the study, including cycling and jumping tests * Give blood samples to measure iron levels * Provide stool and intestinal samples to study gut bacteria * Swallow a SIMBA capsule before and after the study to collect a sample from the small intestine * Complete regular online surveys about sleep, stress, menstrual cycles, and gut symptoms
Waitlist Available
Has No Placebo
University of CalgaryJane ShearerMitacs
Have you considered Thyrosafe clinical trials? We made a collection of clinical trials featuring Thyrosafe, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security